spacer
home > ict > spring 2021 > a patient-centric approach to clinical trials
PUBLICATIONS
International Clinical Trials

A Patient-Centric Approach to Clinical Trials



Clinical trials are critical for the delivery of safe, new medicines to the global marketplace. This area continues to grow exponentially as new investment is injected into medical research and drug development. The clinical trials market as a whole is expected to grow at 5.7% per year to an overall value of $69.5 billion by 2028. To put this in perspective, in the year 2000, there were approximately 2,100 trials registered; by 2019, this number had grown to over 280,000 active trials.

But traditional trials are problematic for a number of reasons, leading to high costs and inefficiencies. They are logistically demanding from the onset. Recruiting volunteers and patients, and then being able to retain them, has long been a problem. With the world expected to see more infectious disease outbreaks in future, traditional trial models and practices are no longer sustainable. We need a new and innovative approach to clinical trials – one that will ensure patients have access to lifesaving treatments regardless of black swan events like the global pandemic. Luckily, the industry is coming together under these pressures to innovate and modernise.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the Author

Carolina Rossi Wosiack is Managing Director of EMEA at CI&T. Carolina is a seasoned digital executive with nearly 20 years of experience in innovative processes, people, and products, combining strategic and analytic insights and various strategy methods across design thinking and growth strategies. She has applied her expertise on a global scale across several industries in Europe, Brazil, the US, and LATAM, ranging from pharmaceuticals to consumer goods, banking, and telecommunications. Carolina has helped transform leading companies such as Roche, Sanofi, Johnson & Johnson, and Ericsson to prepare and adjust their business for rapid adaptation in the digital world.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Evonetix Commences Early Access Program for DNA Synthesised by Thermal Control on its Semiconductor Chip

Cambridge, UK 16th August 2022 – EVONETIX LTD (‘Evonetix’), the synthetic biology company bringing semiconductor technology to DNA synthesis, today announced the opening of its early access program for semiconductor synthesised DNA. Evonetix’s DNA synthesis capability brings together patented semiconductor chip design and proprietary, thermally controlled synthesis chemistry, which will be integral to the Company’s future gene synthesis platforms.
More info >>

White Papers

Backward Thinking

Development of a generic equivalent to a current marketed pressurized metered dose inhaler (pMDI) product brings immense challenges. Thorough analysis is critical to gain a comprehensive understanding of the physical attributes and pharmaceutical performance of the reference marketed product. Many factors need to be assessed, understood and combined in order to successfully develop a generic pMDI which will meet the regulatory and quality requirements as an equivalent product in the anticipated target market.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement